## PRIOR AUTHORIZATION FORM

GLP-1 RA Products - Commercial



Unless otherwise indicated below, authorization quantities are limited to the manufacturer recommended dosage

P.O. Box 30192 Salt Lake City, UT 84130

Complete online at www.selectheal	th.org/pa or fax back to: 801-650-3279
For questions or clarifications, call: 800-442-3129	
Patient Information	
Patient's Name:	Patient's Date of Birth:
Patient's ID:	Patient's Phone #:
Diagnosis Code(s):	
Requesting Provider Information	
Name:	Phone #:
NPI/DEA:	Fax #:
Address:	Supervising Physician (if requesting provider bills under a different provider)  Name:
	NPI/DEA:
Servicing Provider Information (if	different than requesting provider)
Name of provider or facility:	Phone number:
*	
NPI/DEA:	Address:
Drug Name and Strength:	Directions / SIG:
Q1. What medication is being requested?  □ Bydureon BC □ Byetta □ Trulicity □ Mounjaro	
Q2. What is the patient's diagnosis?  ☐ Type 2 diabetes mellitus ☐ Type 1 diabetes mellitus ☐ Other  Q3. If other, please specify:	

Q4. Has the patient failed metformin or a metformin combination drug?		
☐ Yes	□ No	
(SGLT-2) inhibitor (e.g. Farxiga, Glyxambi, or a dipeptidyl peptidase IV (DPP-4) inhibit	ay trial of a sodium-glucose contransporter-2 Invokamet, Segluromet, Synjardy, Xigduo etc.), or (e.g. alogliptin, Januvia, Onglyza, Tradjenta an or equal to 7 percent in the last 3 months?  ☐ No	
Q6. If no, does the patient have ONE of the following contraindications?		
<ul> <li>☐ Reduced renal function (eGFR 45mL/m</li> <li>☐ Urinary frequency due to BPH, LUTS, b</li> <li>☐ Recurrent genital fungal infection</li> <li>☐ Recurrent urinary tract infection</li> <li>☐ Intolerance to an SGLT2 or DDP4 inhib</li> <li>☐ None of the above</li> </ul>	oladder spasm, etc.	
Q7. Does the patient have an A1c of greatemonths?	er than or equal to 7 percent in the last 3	
☐ Yes	□ No	
Q8. Additional comments:		
This form is intended for SelectHealth members only. All requests for preauthorization should be sent via fax to 1-801-650-3279.  Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.		
Prescriber Signature	Date	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document